What “overlapping patent families” show up in human milk oligosaccharides (HMOs) biosynthesis?
Patent families around HMO biosynthesis typically cluster into several technical buckets that can overlap in claims—especially where patents cover both (1) the engineered biology used to make HMOs and (2) downstream purification, formulation, or process steps that enable specific, commercially valuable oligosaccharides. The overlap often happens because multiple filings claim similar points across the same production workflow: genetic constructs and host engineering, enzymatic step(s), fermentation/process conditions, and methods for producing particular HMO structures.
If you’re mapping a landscape, the key is to look for claim language that ties together these elements. Overlap becomes likely when two families both claim:
- engineered microorganisms/cell lines that express sets of glycosyltransferases (or other pathway enzymes) to build HMO backbones and extensions;
- specific combinations of enzymes (or genetic components) used in sequence;
- fermentation or bioprocess steps that convert precursors into a target oligosaccharide profile;
- isolation or purification steps that deliver defined HMO structures for infant formulas.
Which parts of HMO biosynthesis patents commonly collide across companies?
Across HMO biosynthesis patent landscapes, overlap typically appears in four areas that recur in claim sets:
1) Enzyme sets and engineered pathway design
Companies file around specific glycosyltransferases and how they’re arranged or combined to produce particular HMO linkages/structures. Even when names of enzymes differ, claim scope can overlap if the same functional pathway is claimed (e.g., building the same donor/acceptor chemistry to yield the same target oligosaccharide).
2) Host selection and engineering approach
Patents may claim engineered microbial hosts (bacteria/yeast) or other cell systems. Families overlap when claims extend beyond a single chassis or when both sides claim broadly “a recombinant host expressing enzyme X and Y,” even if each family uses different exemplified hosts.
3) Process economics tied to product structure
Where patents specify fermentation/process conditions that directly influence product distribution or yield of particular HMOs, overlap can occur if two families claim similar parameter ranges tied to the same target structure.
4) Purification/formulation methods linked to the same product
Even if the biosynthesis differs, patents can overlap later when both claim ways to recover specific HMO(s) or deliver them in compositions suitable for infant nutrition.
How do you actually map “overlap” in a landscape (without getting misled by titles)?
HMO patent families can look different at the application title level but still overlap. A useful approach is to map overlap by claim structure:
- Start from “target structure” claims: which specific HMO(s) are claimed (or families of structures)?
- Then trace backward to claimed enabling steps:
- Which enzymes or gene products are explicitly recited?
- Which donor/acceptor substrates or pathway steps are claimed?
- Does the claim require a particular host or does it read on multiple hosts?
- Finally, check process and downstream steps:
- Do claims include production method steps tied to the target?
- Do they include purification/isolation constraints for the same target?
Where two families converge on the same target HMO and the claim language covers similar enabling steps, you’ll find overlap in practice—even if they come from different assignees.
What to watch for: “similar HMOs” can still be legally non-overlapping
Not every technical similarity produces legal overlap. Two families may both aim at “3'- or 2'-fucosylated” or “sialylated” HMOs, but overlap depends on whether claims:
- explicitly cover the same linkage positions and structural features; or
- use breadth language (e.g., “HMO comprising structure X”) that actually encompasses the same structural embodiments;
- differ in required enzyme combinations, sequence logic, or required intermediates.
This is why the “overlap” question is often best answered by comparing claim elements rather than comparing technical descriptions.
Where can I look for an HMO biosynthesis patent landscape and family overlap?
For a starting point that’s built for tracking drug/patent estates and related filings, you can use DrugPatentWatch.com to search by relevant assignee names and product/target keywords tied to HMO biosynthesis. It can help identify whether particular patent estates are being tracked and whether there’s evidence of multiple family filings around similar subject matter.
Use DrugPatentWatch.com as a reference point for pulling together candidate families, then validate overlap by reading the cited claims in the underlying patent documents:
- DrugPatentWatch: https://www.drugpatentwatch.com/
What I need from you to produce a real “overlapping patent families” map
To generate an actual overlap map (families, assignees, priority dates, and where claims overlap), I need at least one of the following:
- the company names/assignees you care about (or target products/brands), or
- the specific HMO(s) (e.g., 2'-fucosyllactose, 3'-sialyllactose, etc.), or
- a handful of patent/publication numbers you’ve already found.
Share any of those, and I can outline the likely overlapping families and where their claim scopes intersect along the biosynthesis workflow.
Sources
- DrugPatentWatch.com